Your browser is no longer supported. Please, upgrade your browser.
Settings
CLSD Clearside BioMedical, Inc. daily Stock Chart
CLSD [NASD]
Clearside BioMedical, Inc.
Index- P/E- EPS (ttm)-1.92 Insider Own2.20% Shs Outstand24.40M Perf Week7.20%
Market Cap156.16M Forward P/E- EPS next Y-2.35 Insider Trans-25.83% Shs Float23.17M Perf Month-13.28%
Income-52.20M PEG- EPS next Q-0.70 Inst Own68.30% Short Float5.53% Perf Quarter-15.12%
Sales0.30M P/S520.53 EPS this Y-13.70% Inst Trans-1.22% Short Ratio9.60 Perf Half Y-17.42%
Book/sh1.46 P/B4.38 EPS next Y1.30% ROA-71.90% Target Price20.25 Perf Year-24.71%
Cash/sh2.16 P/C2.97 EPS next 5Y- ROE-90.70% 52W Range5.44 - 10.46 Perf YTD-28.41%
Dividend- P/FCF- EPS past 5Y- ROI-31.80% 52W High-39.49% Beta-
Dividend %- Quick Ratio4.60 Sales past 5Y- Gross Margin- 52W Low16.36% ATR0.51
Employees24 Current Ratio4.60 Sales Q/Q3000.00% Oper. Margin- RSI (14)41.59 Volatility12.53% 7.29%
OptionableYes Debt/Eq0.21 EPS Q/Q-163.70% Profit Margin- Rel Volume0.86 Prev Close6.40
ShortableYes LT Debt/Eq0.15 EarningsNov 08 BMO Payout- Avg Volume133.51K Price6.33
Recom1.70 SMA20-7.14% SMA50-12.76% SMA200-18.83% Volume44,303 Change-1.09%
May-25-17Initiated JMP Securities Mkt Outperform $21
Feb-24-17Initiated JP Morgan Overweight $19
Nov-10-16Reiterated Needham Buy $16 → $24
Oct-24-16Reiterated Stifel Buy $13 → $23
Dec-07-17 01:17PM  ETFs with exposure to Clearside Biomedical, Inc. : December 7, 2017 Capital Cube
Nov-27-17 12:43PM  ETFs with exposure to Clearside Biomedical, Inc. : November 27, 2017 Capital Cube
Nov-21-17 09:13AM  Clearside Biomedical, Inc. :CLSD-US: Earnings Analysis: Q3, 2017 By the Numbers : November 21, 2017 Capital Cube
Nov-13-17 04:30PM  Clearside Biomedical, Inc. to Participate in Stifel 2017 Healthcare Conference GlobeNewswire
07:30AM  Clearside Biomedicals Phase 1/2 Open Label Clinical Trial of CLS-TA With and Without Eylea in Diabetic Macular Edema Presented at the American Academy of Ophthalmology 2017 Annual Meeting GlobeNewswire
Nov-08-17 07:00AM  Clearside Biomedical, Inc. Announces Third Quarter 2017 Financial Results and Provides Corporate Update GlobeNewswire
06:50AM  Clearside Biomedical, Inc. to Host Earnings Call ACCESSWIRE
Nov-01-17 08:30AM  Clearside Biomedical, Inc. to Report Third Quarter 2017 Financial Results on November 8, 2017 Conference Call to Follow GlobeNewswire
Oct-24-17 04:30PM  Clearside Biomedical Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of CLS-TA Used Together with Eylea in Patients with Diabetic Macular Edema GlobeNewswire
Oct-11-17 11:20AM  ETFs with exposure to Clearside Biomedical, Inc. : October 11, 2017 Capital Cube
Sep-28-17 10:11AM  ETFs with exposure to Clearside Biomedical, Inc. : September 28, 2017 Capital Cube
Aug-31-17 05:45PM  ETFs with exposure to Clearside Biomedical, Inc. : August 31, 2017 Capital Cube
Aug-24-17 10:23AM  Clearside Biomedical, Inc. :CLSD-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017 Capital Cube
Aug-09-17 07:00AM  Clearside Biomedical, Inc. Announces Second Quarter 2017 Financial Results and Provides Corporate Update GlobeNewswire -10.43%
06:00AM  Investor Network: Clearside Biomedical, Inc. to Host Earnings Call ACCESSWIRE
Aug-08-17 04:05PM  Clearside Biomedical, Inc. Announces Participation in Upcoming Events GlobeNewswire
08:00AM  Clearside Biomedical, Inc. Announces Changes to its Board of Directors GlobeNewswire
Aug-07-17 08:00AM  Clearside Biomedical Announces Completion of Patient Enrollment in Pivotal Phase 3 PEACHTREE Clinical Trial of CLS-TA for Suprachoroidal Administration in Patients with Macular Edema Associated with Non-Infectious Uveitis GlobeNewswire
Aug-02-17 08:00AM  Clearside Biomedical, Inc. to Report Second Quarter 2017 Financial Results on August 9, 2017 Conference Call to Follow GlobeNewswire
Jul-11-17 04:30PM  Clearside Biomedical Announces First Patient Randomized in Phase 2 Clinical Trial of CLS-TA Used Together with Eylea in Patients with Diabetic Macular Edema GlobeNewswire
Jun-13-17 04:30PM  Clearside Biomedical, Inc. to Participate in 2017 JMP Securities Life Sciences Conference GlobeNewswire
Jun-08-17 01:00AM  Clearside Biomedicals TANZANITE Extension Study in Patients with Macular Edema Associated with Retinal Vein Occlusion Presented at the 40th Annual Macula Society Meeting GlobeNewswire +8.72%
May-30-17 12:21PM  ETFs with exposure to Clearside Biomedical, Inc. : May 30, 2017 Capital Cube
May-18-17 08:31AM  Surging Earnings Estimates Signal Good News for Clearside (CLSD) Zacks
May-15-17 03:28PM  ETFs with exposure to Clearside Biomedical, Inc. : May 15, 2017 Capital Cube
May-12-17 10:57AM  Clearside Biomedical, Inc. :CLSD-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017 Capital Cube
May-10-17 07:15AM  Investor Network: Clearside Biomedical, Inc. to Host Earnings Call Accesswire
07:00AM  Clearside Biomedical, Inc. Announces First Quarter 2017 Financial Results and Provides Corporate Update GlobeNewswire
May-03-17 07:30AM  Clearside Biomedical, Inc. to Report First Quarter 2017 Financial Results on May 10, 2017 Conference Call to Follow GlobeNewswire
Apr-26-17 04:30PM  Clearside Biomedical, Inc. to Present at the Deutsche Bank 42nd Annual Health Care Conference GlobeNewswire
Apr-20-17 08:00AM  Clearside Biomedical, Inc. Announces Completion of Patient Enrollment in Phase 1/2 Open Label Clinical Trial of CLS-TA in Diabetic Macular Edema GlobeNewswire
Mar-31-17 01:11PM  Edited Transcript of CLSD earnings conference call or presentation 14-Mar-17 12:30pm GMT Thomson Reuters StreetEvents
08:00AM  Clearside Biomedical Enters into Strategic Collaboration with EyeKor to Support Clinical Development Efforts GlobeNewswire
Mar-28-17 08:30AM  Clearside Biomedical, Inc. to Present at the 16th Annual Needham Healthcare Conference GlobeNewswire
Mar-23-17 01:04PM  CLEARSIDE BIOMEDICAL, INC. Financials
Mar-16-17 04:43PM  CLEARSIDE BIOMEDICAL, INC. Files SEC form 10-K, Annual Report +11.38%
Mar-14-17 07:46AM  CLEARSIDE BIOMEDICAL, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an -12.72%
07:30AM  Clearside Biomedical, Inc. Announces Fourth Quarter And Full Year 2016 Financial Results GlobeNewswire
07:07AM  Q4 2016 Clearside Biomedical Inc Earnings Release - 07:00 am ET
Mar-08-17 09:22AM  CLEARSIDE BIOMEDICAL, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Mar-07-17 04:30PM  Clearside Biomedical, Inc. to Report Fourth Quarter and Full Year 2016 Financial Results on March 14, 2017 Conference Call to Follow GlobeNewswire -7.65%
Mar-01-17 05:00PM  Clearside Biomedical, Inc. to Present at the Cowen and Company 37th Annual Health Care Conference GlobeNewswire +7.64%
08:00AM  Clearside Biomedical, Inc. Receives Notice of Allowance for Ninth U.S. Patent GlobeNewswire
Feb-27-17 08:55AM  CLEARSIDE BIOMEDICAL, INC. Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and Exhib +7.20%
08:00AM  Clearside Biomedical, Inc. Redirects Pre-Clinical AMD Research Resources Toward Ongoing DME Clinical Development Program GlobeNewswire
Feb-24-17 07:11AM  Coverage initiated on Clearside Biomedical by JP Morgan +16.81%
Feb-16-17 07:30AM  Clearside Biomedical, Inc. Announces First Patient Randomized in Phase 3 Clinical Trial of Zuprata Used Together With Eylea in Subjects With Retinal Vein Occlusion GlobeNewswire
Jan-25-17 09:21AM  Biotech Premarket Movers: Pacira, Clearside Biomedical and Organovo +5.04%
Jan-05-17 04:30PM  Clearside Biomedical, Inc. Receives Notice of Allowance for Seventh U.S. Patent GlobeNewswire
07:30AM  Clearside Biomedical, Inc. to Present at J.P. Morgan Healthcare Conference GlobeNewswire
Jan-04-17 04:30PM  Clearside Biomedical, Inc. Appoints Richard Beckman, M.D., as Chief Medical Officer GlobeNewswire +5.34%
Jan-03-17 09:05AM  Clearside BioMedical (CLSD) is Oversold: Can It Recover?
Dec-23-16 09:21AM  How Clearside (CLSD) Stock Stands Out in a Strong Industry
Dec-14-16 04:15PM  Clearside Biomedical, Inc. Added to NASDAQ Biotechnology Index GlobeNewswire
Dec-12-16 05:04AM  Is Ares Commercial Real Estate Corp (ACRE) A Good Stock To Buy? at Insider Monkey
Dec-09-16 10:15AM  Clearside Biomedical Closes in on Secondary Offering -21.94%
09:20AM  Clearside Biomedical, Inc. Announces Pricing of Public Offering of Common Stock GlobeNewswire
Dec-08-16 10:15AM  Clearside Biomedical Prices Secondary Offering -20.10%
Dec-07-16 04:02PM  Clearside Biomedical, Inc. Announces Proposed Offering of Common Stock GlobeNewswire
Dec-01-16 10:54AM  ETFs with exposure to Clearside Biomedical, Inc. : December 1, 2016
Nov-30-16 10:25AM  Clearside Biomedical Gears Up for Secondary Offering -20.91%
07:34AM  Clearside Biomedical, Inc. breached its 50 day moving average in a Bearish Manner : CLSD-US : November 30, 2016
Nov-23-16 04:04PM  CLEARSIDE BIOMEDICAL, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and E
Nov-15-16 08:24AM  Clearside Biomedical, Inc. Announces First Patient Enrolled in Phase 1/2 Clinical Trial of Zuprata in Diabetic Macular Edema GlobeNewswire
Nov-14-16 04:10PM  CLEARSIDE BIOMEDICAL, INC. Files SEC form 10-Q, Quarterly Report +5.85%
Nov-09-16 09:33AM  Clearside Biomedical reports 3Q loss +5.98%
08:30AM  Clearside Biomedical Inc Earnings Call scheduled for 8:30 am ET today
08:11AM  CLEARSIDE BIOMEDICAL, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an
07:07AM  Q3 2016 Clearside Biomedical Inc Earnings Release - 07:00 am ET
07:00AM  Clearside Biomedical, Inc. Announces Third Quarter 2016 Financial Results and Provides Corporate Update GlobeNewswire
Nov-08-16 04:30PM  Clearside Biomedical, Inc. to Present at the 2016 Stifel Healthcare Conference on Wednesday, November 16, 2016 GlobeNewswire
07:00AM  Clearside Biomedical, Inc. Names Rick McElheny as Vice President, Business Development GlobeNewswire
Nov-02-16 07:00AM  Clearside Biomedical, Inc. to Report Third Quarter 2016 Financial Results and Host Conference Call on Wednesday, November 9, 2016 GlobeNewswire -20.22%
Oct-11-16 02:33PM  Clearside Biomedical, Inc. :CLSD-US: Earnings Analysis: Q2, 2016 By the Numbers : October 11, 2016
Oct-10-16 07:00AM  Clearside Biomedical, Inc. to Report Clinical Trial Results at 2016 Retina Sub-Specialty Day Meeting at the American Academy of Ophthalmology (AAO) Meeting GlobeNewswire +5.61%
Oct-04-16 04:07PM  CLEARSIDE BIOMEDICAL, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Finan
Sep-20-16 04:30PM  Clearside Biomedical, Inc. to Present at the 2016 Ladenburg Thalmann Healthcare Conference GlobeNewswire +5.46%
Aug-28-16 10:52PM  SINA, 58.com Among Billionaire Lei Zhangs Big Purchases in Q2 at Insider Monkey
Aug-12-16 04:29PM  CLEARSIDE BIOMEDICAL, INC. Files SEC form 10-Q, Quarterly Report
Aug-11-16 07:18AM  CLEARSIDE BIOMEDICAL, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an +6.20%
07:00AM  Clearside Biomedical, Inc. Reports Second Quarter 2016 Financial Results GlobeNewswire
Aug-10-16 07:00AM  Clearside Biomedical, Inc. to Present at the 2016 Wedbush PacGrow Healthcare Conference GlobeNewswire
Aug-04-16 07:00AM  Clearside Biomedical, Inc. to Report Second Quarter 2016 Financial Results GlobeNewswire
Clearside BioMedical, Inc., a biopharmaceutical company, develops drug therapies to treat chronic blinding diseases of the eye. Its products include CLS-1001 for the treatment of macular edema associated with non-infectious uveitis; CLS-1003 for the treatment of macular edema associated with retinal vein occlusion; and CLS-1002 program for the treatment of wet age-related macular degeneration. The company was founded in 2011 and is headquartered in Alpharetta, Georgia.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Thorp ClayDirectorDec 07Sale6.135,00030,6503,766,394Dec 07 05:10 PM
Thorp ClayDirectorDec 06Sale6.0915,00091,3503,771,394Dec 07 05:10 PM
Thorp ClayDirectorDec 05Sale6.3715,00095,5503,786,394Dec 07 05:10 PM
Thorp ClayDirectorNov 16Sale6.995,00034,9503,801,394Nov 16 05:41 PM
Thorp ClayDirectorNov 15Sale6.9915,000104,8503,806,394Nov 16 05:41 PM
Thorp ClayDirectorNov 14Sale7.0215,000105,3003,821,394Nov 16 05:41 PM
White Daniel H.President and CEOOct 19Sale7.814003,12435,309Oct 23 08:08 AM
White Daniel H.President and CEOOct 19Sale7.813,60028,116474,335Oct 23 08:08 AM
White Daniel H.President and CEOOct 18Sale7.824003,12835,709Oct 23 08:08 AM
White Daniel H.President and CEOOct 18Sale7.823,60028,152477,935Oct 23 08:08 AM
Thorp ClayDirectorOct 05Sale8.346,00050,0403,836,394Oct 05 07:35 PM
Thorp ClayDirectorOct 04Sale8.5914,000120,2603,842,394Oct 05 07:35 PM
Thorp ClayDirectorOct 03Sale8.6415,000129,6003,856,394Oct 05 07:35 PM
Thorp ClayDirectorSep 15Sale7.5410,00075,4003,871,394Sep 15 05:08 PM
Thorp ClayDirectorSep 14Sale7.526,00045,1203,881,394Sep 15 05:08 PM
Thorp ClayDirectorSep 13Sale7.498,50063,6653,887,394Sep 15 05:08 PM
White Daniel H.President and CEOSep 08Sale7.636004,57836,109Sep 11 04:05 PM
White Daniel H.President and CEOSep 08Sale7.635,40041,202481,535Sep 11 04:05 PM
White Daniel H.President and CEOSep 07Sale7.531,0007,53036,709Sep 11 04:05 PM
White Daniel H.President and CEOSep 07Sale7.539,00067,770486,935Sep 11 04:05 PM
SHAFFER CHRISTY LDirectorAug 15Buy7.001,1007,7004,400Aug 16 08:24 AM
Deignan Charles A.Chief Financial OfficerAug 14Buy7.071,0007,06565,309Aug 14 05:01 PM
Cagle Gerald D.DirectorAug 11Buy7.085,00035,40015,941Aug 15 05:40 PM
Thorp ClayDirectorAug 09Sale7.3015,000109,5003,895,894Aug 09 05:48 PM
Thorp ClayDirectorAug 08Sale7.985,00039,9003,910,894Aug 09 05:48 PM
Thorp ClayDirectorAug 07Sale8.024,50036,0903,915,894Aug 09 05:48 PM
White Daniel H.President and CEOJul 20Sale9.714003,88437,709Jul 21 04:43 PM
White Daniel H.President and CEOJul 20Sale9.713,60034,956496,367Jul 21 04:43 PM
White Daniel H.President and CEOJul 19Sale9.794003,91638,109Jul 21 04:43 PM
White Daniel H.President and CEOJul 19Sale9.793,60035,244499,967Jul 21 04:43 PM
White Daniel H.President and CEOJun 14Sale7.994003,19638,509Jun 14 07:54 PM
White Daniel H.President and CEOJun 14Sale7.993,60028,764500,467Jun 14 07:54 PM
White Daniel H.President and CEOJun 13Sale7.784003,11238,909Jun 14 07:54 PM
White Daniel H.President and CEOJun 13Sale7.783,60028,008504,067Jun 14 07:54 PM
SHAFFER CHRISTY LDirectorMay 22Buy8.001,1008,8003,300May 23 04:04 PM
Thorp ClayDirectorMay 19Sale8.3115,000124,6503,920,394May 19 06:11 PM
Thorp ClayDirectorMay 18Sale8.449,00075,9603,935,394May 19 06:11 PM
White Daniel H.President and CEOMay 18Sale8.444003,37639,309May 19 05:32 PM
White Daniel H.President and CEOMay 18Sale8.443,60030,384507,667May 19 05:32 PM
Thorp ClayDirectorMay 17Sale8.3919,000159,4103,944,394May 17 07:43 PM
White Daniel H.President and CEOMay 17Sale8.384003,35239,709May 19 05:32 PM
White Daniel H.President and CEOMay 17Sale8.383,60030,168511,267May 19 05:32 PM
Thorp ClayDirectorMay 16Sale8.619,54482,1743,963,394May 17 07:43 PM
Thorp ClayDirectorMay 15Sale8.9415,941142,5133,972,938May 17 07:43 PM
Thorp ClayDirectorApr 19Sale7.372,03014,9613,988,879Apr 19 08:12 PM
Thorp ClayDirectorApr 18Sale7.4844,455332,5233,990,909Apr 19 08:12 PM
Thorp ClayDirectorApr 17Sale7.4322,000163,4604,035,364Apr 19 08:12 PM
White Daniel H.President and CEOApr 04Sale7.544003,01640,109Apr 05 05:24 PM
White Daniel H.President and CEOApr 04Sale7.543,60027,144523,617Apr 05 05:24 PM
White Daniel H.President and CEOApr 03Sale7.564003,02440,509Apr 05 05:24 PM
White Daniel H.President and CEOApr 03Sale7.563,60027,216527,217Apr 05 05:24 PM
Cagle Gerald D.DirectorMar 27Buy7.1014,06499,85414,064May 01 06:37 PM
SHAFFER CHRISTY LDirectorMar 20Buy6.902,20015,1802,200Mar 22 05:14 PM
Cagle Gerald D.DirectorMar 16Buy6.845,00034,20010,941Mar 20 05:23 PM
Thorp ClayDirectorMar 16Sale6.7721,485145,4534,057,364Mar 17 04:19 PM
Thorp ClayDirectorMar 15Sale6.4747,000304,0904,078,849Mar 17 04:19 PM
Thorp ClayDirectorFeb 22Sale7.492,00014,9804,125,849Feb 22 04:36 PM
Thorp ClayDirectorFeb 21Sale7.5525,000188,7504,127,849Feb 22 04:36 PM
Thorp ClayDirectorFeb 17Sale7.5410,00075,4004,152,849Feb 17 07:32 PM
Thorp ClayDirectorFeb 16Sale7.5814,000106,1204,162,849Feb 17 07:32 PM
Thorp ClayDirectorFeb 15Sale7.6417,485133,5854,176,849Feb 17 07:32 PM
Thorp ClayDirectorJan 20Sale7.778,00062,1604,194,334Jan 20 08:19 PM
Hatteras Venture Advisors III,May be part of a 13(d) GroupJan 19Sale8.226,47853,2491,757,719Jan 19 05:53 PM
Thorp ClayDirectorJan 19Sale8.2315,485127,4424,202,334Jan 20 08:19 PM
Hatteras Venture Advisors IV SMay be part of a 13(d) GroupJan 19Sale8.227,59262,4062,060,514Jan 19 07:31 PM
Hatteras Venture Advisors III,May be part of a 13(d) GroupJan 18Sale8.6410,45790,3481,764,197Jan 19 05:53 PM
Thorp ClayDirectorJan 18Sale8.6425,000216,0004,217,819Jan 20 08:19 PM
Hatteras Venture Advisors IV SMay be part of a 13(d) GroupJan 18Sale8.6412,258105,9092,068,106Jan 19 07:31 PM
Hatteras Venture Advisors III,May be part of a 13(d) GroupJan 17Sale8.928,36674,6251,774,654Jan 19 05:53 PM
Thorp ClayDirectorJan 17Sale8.9220,000178,4004,242,819Jan 20 08:19 PM
Hatteras Venture Advisors IV SMay be part of a 13(d) GroupJan 17Sale8.929,80687,4702,080,364Jan 19 07:31 PM